<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142814">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01759784</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Nerve-004</org_study_id>
    <nct_id>NCT01759784</nct_id>
  </id_info>
  <brief_title>Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS</brief_title>
  <official_title>Safety of Intraventricular Injection of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALS is a debilitating disease with varied etiology characterized by rapidly progressive
      weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking
      (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is
      the most common of the five motor neuron diseases.Riluzole (Rilutek) is the only treatment
      that has been found to improve survival but only to a modest extent. It lengthens survival
      by several months, and may have a greater survival benefit for those with a bulbar onset. It
      also extends the time before a person needs ventilation support.Stem cell transplantation is
      a new hopeful way to improve the patients conditions and reduce the period of disabilities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study our purpose is to evaluate the safety of intraventricular injection of bone
      marrow derived mesenchymal stem cell.the patients who are eligible,underwent bone marrow
      aspiration.after cell separation and preparation,the patients underwent mesenchymal stem
      cell intraventricular injection by stereotaxis.after injection he will be under observed in
      ICU to monitor the adverse events(allergic and neurological side effects).patients are
      followed 1th,3th ,6th and 12 months after injection and each time these parameters are
      checked:ALS-FRS,EMG-NCV,FVC,side effect check list.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>fever</measure>
    <time_frame>48hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>evaluation the rate of fever 48hours after stem cell injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>unconsciousness</measure>
    <time_frame>6months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>evaluation the rate of unconsciousness during 6months after stem cell injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>brain hematoma</measure>
    <time_frame>48hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation the rate of hematoma 48hours after stem cell injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vomiting</measure>
    <time_frame>48hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>evaluation the rate of vomiting 48hours after stem cell injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALS-FRS</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation the improvement of ALS-FRS 6months after stem cell injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMG-NCV</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation the improvement of EMG-NCV after stem cell injection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>stem cell recipient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients who underwent mesenchymal stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intraventricular injection</intervention_name>
    <description>intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS</description>
    <arm_group_label>stem cell recipient</arm_group_label>
    <other_name>intraventricular injection of mesenchymal stem cell by stereotaxis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:18-65

          -  both gender

          -  duration of disease&lt;2 years

          -  FVC&gt;40% ALS-FRS&gt;26

        Exclusion Criteria:

          -  neurological and psychiatric concomitant disease

          -  concomitant systemic disease

          -  treatment with corticosteroid,Ig,immunosuppressive during 12 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Royan department of degenerative medicine,Head of Royan celltherapy center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Reza Zali, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Neurosurgery research center of Shahid Beheshti University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <phone>+9821235622000</phone>
    <phone_ext>504</phone_ext>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>+982123562000</phone>
    <phone_ext>414</phone_ext>
    <email>leara91@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Aghdami, MD,PhD</last_name>
      <phone>+982123562000</phone>
      <phone_ext>504</phone_ext>
      <email>nasser.aghdami@royaninstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Leila Arab, MD</last_name>
      <phone>+982123562000</phone>
      <phone_ext>414</phone_ext>
      <email>Leara91@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Leila Arab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farzad Ashraafi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soura Mardpour, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vagihe Azimian, PhD student</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
  </link>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>December 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stem cell intraventricular injection ALS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
